English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/124595
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

FAS system deregulation in T-cell lymphoblastic lymphoma

AuthorsVilla-Morales, María ; Cobos-Fernández, M. A. ; González-Gugel, Elena ; Álvarez-Iglesias, V.; Martínez, B.; Piris, Miguel Ángel; Carracedo, Angel; Benítez, Javier; Fernández-Piqueras, José
Issue Date6-Mar-2014
PublisherNature Publishing Group
CitationCell Death & Disease 5: 1110 (2014)
AbstractThe acquisition of resistance towards FAS-mediated apoptosis may be required for tumor formation. Tumors from various histological origins exhibit FAS mutations, the most frequent being hematological malignancies. However, data regarding FAS mutations or FAS signaling alterations are still lacking in precursor T-cell lymphoblastic lymphomas (T-LBLs). The available data on acute lymphoblastic leukemia, of precursor origin as well, indicate a low frequency of FAS mutations but often report a serious reduction in FAS-mediated apoptosis as well as chemoresistance, thus suggesting the occurrence of mechanisms able to deregulate the FAS signaling pathway, different from FAS mutation. Our aim at this study was to determine whether FAS-mediated apoptotic signaling is compromised in human T-LBL samples and the mechanisms involved. This study on 26 T-LBL samples confirms that the FAS system is impaired to a wide extent in these tumors, with 57.7% of the cases presenting any alteration of the pathway. A variety of mechanisms seems to be involved in such alteration, in order of frequency the downregulation of FAS, the deregulation of other members of the pathway and the occurrence of mutations at FAS. Considering these results together, it seems plausible to think of a cumulative effect of several alterations in each T-LBL, which in turn may result in FAS/FASLG system deregulation. Since defective FAS signaling may render the T-LBL tumor cells resistant to apoptotic cell death, the correct prognosis, diagnosis and thus the success of anticancer therapy may require such an in-depth knowledge of the complete scenario of FAS-signaling alterations.
URIhttp://hdl.handle.net/10261/124595
DOIhttp://dx.doi.org/10.1038/cddis.2014.83
Identifiersdoi: 10.1038/cddis.2014.83
issn: 2041-4889
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
FernandezPiqueras_FASSystemDeregulation.pdf1,55 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.